Litcius/Paper detail

Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial

Shun Lü, Lin Wu, Hong Jian, Ying Cheng, Qiming Wang, Jian Fang, Ziping Wang, Yanping Hu, Liang Han, Meili Sun, Liyun Miao, Cuimin Ding, Jiuwei Cui, Ke Wang, Baolan Li, Xingya Li, Feng Ye, Anwen Liu, Yueyin Pan, Shundong Cang, Hui Zhou, Xing Sun, Yuping Shen, Shuyan Wang, Wen Zhang, Yue He

2023The Lancet Respiratory Medicine201 citationsDOI

Topics & Concepts

PemetrexedMedicineInternal medicineChemotherapyLung cancerOncologyInterim analysisResponse Evaluation Criteria in Solid TumorsBevacizumabPopulationCisplatinProgressive diseaseClinical trialEnvironmental healthCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsBiosimilars and Bioanalytical Methods
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial | Litcius